Loading...
XNAS
PCRX
Market cap1.01bUSD
Jul 30, Last price  
21.77USD
1D
0.74%
1Q
-18.62%
Jan 2017
-32.60%
IPO
209.67%
Name

Pacira Biosciences Inc

Chart & Performance

D1W1MN
P/E
—
P/S
1.44
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.18%
Rev. gr., 5y
10.73%
Revenues
701m
+3.85%
13,925,00015,006,00014,562,00015,689,00039,084,00085,551,000197,668,000248,997,000276,371,000286,630,000337,277,000421,026,000420,830,000541,533,000666,823,000674,978,000700,966,000
Net income
-100m
L
-41,862,000-31,707,000-27,149,000-43,328,000-52,281,000-63,909,000-13,716,0001,856,000-37,949,000-42,611,000-471,000-11,016,000145,523,00041,980,00015,909,00041,955,000-99,560,000
CFO
189m
+22.46%
-29,189,000-20,838,000-24,880,000-31,000,000-70,130,000-43,216,00025,469,00028,996,00033,453,00017,785,00048,870,00070,520,00077,032,000125,717,000145,274,000154,649,000189,389,000

Profile

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
URL
https://www.pacira.com/
IPO date
Feb 03, 2011
Employees
715
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
700,966
3.85%
674,978
1.22%
666,823
23.14%
Cost of revenue
375,676
530,367
538,608
Unusual Expense (Income)
NOPBT
325,290
144,611
128,215
NOPBT Margin
46.41%
21.42%
19.23%
Operating Taxes
36,454
19,746
(2,607)
Tax Rate
11.21%
13.65%
NOPAT
288,836
124,865
130,822
Net income
(99,560)
-337.30%
41,955
163.72%
15,909
-62.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
(25,000)
(106)
30,295
BB yield
2.87%
0.01%
-1.69%
Debt
Debt current
8,887
17,442
42,769
Long-term debt
489,997
632,209
794,548
Deferred revenue
Other long-term liabilities
38,271
37,791
Net debt
186,461
368,660
484,287
Cash flow
Cash from operating activities
189,389
154,649
145,274
CAPEX
(10,636)
(15,161)
(30,076)
Cash from investing activities
(83,276)
77,541
(225,185)
Cash from financing activities
17,363
(183,031)
(401,528)
FCF
291,541
97,513
107,678
Balance
Cash
276,774
278,581
288,651
Long term investments
35,649
2,410
64,379
Excess cash
277,375
247,242
319,689
Stockholders' equity
(205,966)
(106,503)
(149,085)
Invested Capital
1,458,449
1,600,948
1,725,280
ROIC
18.88%
7.51%
6.75%
ROCE
25.97%
9.68%
8.13%
EV
Common stock shares outstanding
46,245
51,979
46,538
Price
18.84
-44.16%
33.74
-12.61%
38.61
-35.83%
Market cap
871,256
-50.32%
1,753,771
-2.40%
1,796,832
-34.55%
EV
1,057,717
2,122,431
2,281,119
EBITDA
404,075
220,185
219,716
EV/EBITDA
2.62
9.64
10.38
Interest
13,439
20,306
39,976
Interest/NOPBT
4.13%
14.04%
31.18%